Quality of Life Research

, 15:597

Impact of Fatigue in Parkinson’s Disease: The Fatigue Impact Scale for Daily Use (D-FIS)

  • Pablo Martinez-Martin
  • Maria Jose Catalan
  • Julian Benito-Leon
  • Angel Ortega Moreno
  • Ivana Zamarbide
  • Esther Cubo
  • Nadeje van Blercon
  • Victor Campos Arillo
  • Margarita Pondal
  • Gurutz Linazasoro
  • Fernando Alonso
  • Pedro García Ruiz
  • Belen Frades
Article

DOI: 10.1007/s11136-005-4181-0

Cite this article as:
Martinez-Martin, P., Catalan, M.J., Benito-Leon, J. et al. Qual Life Res (2006) 15: 597. doi:10.1007/s11136-005-4181-0

Abstract

The Fatigue Impact Scale for Daily Use (D-FIS) was used in a cross-sectional study including 142 consecutive Parkinson’s disease (PD) patients. Usual clinical measures for PD, the Montgomery-Asberg Depression Rating Scale and the Parkinson’s Disease Questionnaire-8 items were applied. In addition to the D-FIS, patients with fatigue (67.6%, PWF) completed the Multidimensional Fatigue Inventory (MFI), a visual analogue scale for fatigue (VAS-F) and a Global Perception of Fatigue scale (GPF). Relevant psychometric D-FIS results were: floor effect = 4.2%; ceiling effect = 1.1%; skewness = 0.44; item homogeneity = 0.63; Cronbach’s α = 0.93; item-total correlation = 0.68 (item 1)−0.82 (item 8); standard error of measurement = 2.15; convergent validity with other fatigue measures = 0.54 [GPF]−0.62 [VAS-F] (p<0.001). In a multiple linear regression model, fatigue, depression, and disability independently influenced HRQoL, as measured by the PDQ-8. Patients on amantadine had lower prevalence of fatigue. In PD, D-FIS is a consistent and valid measure for fatigue, a frequent symptom previously found to impair patients’ HRQoL. Fatigue was also linked to depression and disability in this study.

Key words

AmantadineAssessmentD-FISFatigueParkinson’s diseasePsychometric attributesQuality of life

Abbreviations

FIS

Fatigue Impact Scale

D-FIS

Fatigue Impact Scale for daily use

GPF

Global Perception of Fatigue scale

HRQoL

Health-related quality of life

HY

Hoehn and Yahr Classification

ISAPD

Intermediate Scale for Assessment of Parkinson’s Disease

IR

Interquartile rank

MADRS

Montgomery-AsbergDepression Rating Scale

MFI

Multidimensional Fatigue Inventory

MFI-GF

Multidimensional Fatigue Inventory-General Fatigue

PD

Parkinson’s disease

PDQ-8

Parkinson’s Disease Questionnaire-8 Items

PDQ-8 SI

Parkinson’s Disease Questionnaire-8 Items Summary Index

PWF

Patients with fatigue

PNF

Patients without fatigue

SES

Schwab and England Scale

UPDRS

Unified Parkinson’s Disease Rating Scale

VAS-F

Visual analogue scale for fatigue

Copyright information

© Springer 2006

Authors and Affiliations

  • Pablo Martinez-Martin
    • 1
    • 11
  • Maria Jose Catalan
    • 2
  • Julian Benito-Leon
    • 3
  • Angel Ortega Moreno
    • 4
  • Ivana Zamarbide
    • 5
  • Esther Cubo
    • 6
  • Nadeje van Blercon
    • 7
  • Victor Campos Arillo
    • 8
  • Margarita Pondal
    • 9
  • Gurutz Linazasoro
    • 7
  • Fernando Alonso
    • 5
  • Pedro García Ruiz
    • 10
  • Belen Frades
    • 1
  1. 1.Unit of Neuroepidemiology, National Centre for EpidemiologyISCIII (Madrid), The Spanish Network HOHSRSpain
  2. 2.Department of NeurologySan Carlos University Teaching Hospital (Madrid)Spain
  3. 3.Department of NeurologyMostoles General Hospital (Madrid)Spain
  4. 4.Department of NeurologyVirgen de las Nieves Hospital (Granada)Spain
  5. 5.Department of NeurologyFuenlabrada General Hospital (Madrid)Spain
  6. 6.Department of NeurologyNuestra Señora del Rosario Clinic (Madrid)Spain
  7. 7.Department of NeurologyQuiron Clinic (San Sebastian)Spain
  8. 8.Department of NeurologyUniversity Teaching Hospital (Malaga)Spain
  9. 9.Department of NeurologySevero Ochoa Hospital (Leganes, Madrid)Spain
  10. 10.Department of NeurologyJimenez Diaz Foundation (Madrid)Spain
  11. 11.Unidad de Neuroepidemiología, Centro Nacional de EpidemiologíaInstituto de Salud Carlos IIIMadridSpain